AdvanCell, a privately held radiopharmaceutical biotechnology company with operations in Australia and the United States, announced on October 22, 2026, updated Phase 1 findings from its TheraPb trial evaluating investigational lead-212-labelled ADVC001 in patients with metastatic androgen pathway modulation-resistant prostate cancer. With a median follow-up of 14.1 months, the company reported an 80% prostate-specific antigen response rate at the selected Phase 2 doses, objective responses in all five patients with evaluable measurable disease, and median radiographic progression-free survival of 11.2 months. The results, disclosed ahead of the company’s ESMO 2026 poster presentation, provide further evidence of anti-tumour activity but remain derived from a small, uncontrolled early-stage study.
The development is relevant to the growing field of targeted radiopharmaceutical therapy, where researchers are investigating whether highly localised radiation delivery can improve outcomes in patients with advanced prostate cancer. ADVC001 uses an alpha-emitting isotope attached to a prostate-specific membrane antigen-targeting molecule, creating a treatment intended to deliver radiation preferentially to cells expressing the target. The updated follow-up also provides information about durability and tolerability beyond the company’s earlier 2025 presentation.
The central question is whether encouraging responses observed during dose escalation can be reproduced in larger populations while maintaining an acceptable safety profile. AdvanCell is now enrolling a Phase 2 expansion programme that will evaluate selected doses and modified treatment schedules across different metastatic prostate cancer settings. That programme will provide a more meaningful assessment of the drug’s development potential than the response percentages generated by the initial 22 participants.
What did the updated TheraPb Phase 1 results reveal about ADVC001 anti-tumour activity?
The TheraPb Phase 1 programme enrolled 22 patients across seven dose and treatment-schedule cohorts. ADVC001 was administered at activities ranging from 60 to 200 megabecquerels, with intervals of one, two, four or six weeks and up to six treatment cycles. The design allowed investigators to examine how different radiation activities and administration schedules affected tolerability and preliminary anti-tumour responses.
As of the October 5, 2026 data cut-off, median follow-up had reached 14.1 months. The updated findings provided approximately 12 additional months of follow-up compared with the earlier results presented at ESMO 2025. AdvanCell reported continued evidence of disease control and no newly identified safety signal during the additional observation period.
At the two selected recommended Phase 2 activities of 160 and 200 megabecquerels, the company reported an 80% PSA50 response rate. PSA50 refers to a reduction of at least 50% in prostate-specific antigen from baseline and is commonly used as a biochemical response measure in prostate cancer studies. Such a reduction can indicate anti-tumour activity, but it does not independently establish prolonged survival or durable clinical benefit.
The company also reported a 100% objective response rate among patients with measurable target lesions assessed under RECIST criteria at those doses. Importantly, this percentage represents five confirmed responses among five evaluable patients, not responses in every participant enrolled in the trial. The denominator is essential because the uncertainty surrounding a response estimate is substantial when the evaluable population is this small.
RECIST objective response measures changes in tumour size according to standardised imaging criteria. It differs from PSA response, which assesses a biochemical marker, and from radiographic progression-free survival, which evaluates the time until imaging-defined progression or death. Agreement between these outcome categories can support the interpretation of anti-tumour activity, but each provides different clinical information.
The company reported a median radiographic progression-free survival of 11.2 months at the selected Phase 2 doses. This represents the estimated median time before radiographic progression or death within the relevant treated population, based on the available follow-up and analysis. However, the announcement did not provide a randomised comparator or the detailed statistical uncertainty surrounding that estimate.
The absence of a control group prevents the results from establishing how much better ADVC001 performs than existing treatment. Patient selection, prior treatment, disease burden and dosing exposure can substantially influence outcomes in early clinical studies. The updated findings therefore support continued investigation rather than a conclusion that the investigational therapy offers superior efficacy.
How does lead-212 targeted alpha therapy differ from established PSMA radioligand treatments?
ADVC001 is designed to deliver radiation using lead-212, an isotope associated with alpha particle emission through its decay chain. The investigational molecule targets prostate-specific membrane antigen, a protein frequently expressed on prostate cancer cells. By attaching the radioactive payload to a PSMA-targeting compound, the treatment is intended to concentrate radiation exposure within target-expressing tumour tissue.
Alpha particles have different physical characteristics from beta particles used in established radioligand therapies. They generally deposit substantial energy over a relatively short distance, producing dense ionisation that can cause difficult-to-repair DNA damage. This characteristic provides a scientific rationale for investigating targeted alpha therapies in cancer.
Lead-212 has a physical half-life of approximately 10.6 hours. Its relatively short half-life can provide advantages and challenges for therapeutic development, depending on the treatment’s pharmacokinetics and manufacturing model. Matching isotope decay characteristics with tumour targeting and normal tissue clearance is a central part of radiopharmaceutical optimisation.
The established PSMA radioligand field includes Novartis’ Pluvicto, or lutetium-177 vipivotide tetraxetan, which delivers beta radiation to PSMA-positive prostate cancer cells. The therapy has demonstrated clinical benefit in defined metastatic castration-resistant prostate cancer populations and has received regulatory authorisation for specified indications. Its clinical success provides a relevant precedent for PSMA-targeted treatment.
However, lead-212 and lutetium-177 therapies should not be ranked solely according to their radiation characteristics. Differences in target binding, biodistribution, administered activity, treatment schedules and patient populations can substantially influence clinical performance. Whether an alpha-emitting approach produces superior efficacy or tolerability must be established through appropriate comparative evidence.
ADVC001’s physicochemical design is intended to support tumour targeting while limiting undesirable radiation exposure to normal tissues. Nevertheless, PSMA expression is not restricted exclusively to prostate cancer cells, and some healthy tissues can receive radiation during treatment. Dosimetry and organ-specific safety assessments are therefore important components of the development programme.
What does the longer follow-up reveal about ADVC001 safety and tolerability?
The updated Phase 1 results are particularly useful because radiopharmaceutical treatment can produce adverse effects that evolve over time. AdvanCell reported that ADVC001 continued to demonstrate favourable tolerability after additional follow-up, with no newly identified safety signal. Most participants completed the six planned treatment cycles according to the study protocol.
The October 2026 announcement did not provide a complete updated table covering every treatment-related adverse event, serious adverse event or laboratory abnormality. Consequently, the company’s characterisation of favourable tolerability should be interpreted alongside the size of the cohort and the limited published numerical detail. An absence of newly reported safety signals does not establish that delayed or uncommon complications cannot occur.
Earlier Phase 1 results presented in 2025 reported no dose-limiting toxicities and no treatment-related serious adverse events during the analysed period. Dry mouth, or xerostomia, was among the observed adverse effects and was predominantly mild. These findings provided an initial basis for selecting doses suitable for further development.
Xerostomia is relevant because salivary glands can express PSMA and may be exposed to PSMA-targeted radiopharmaceuticals. Persistent salivary gland dysfunction can influence eating, speaking and quality of life, making both severity and duration important. The long-term tolerability profile will therefore require attention to more than the incidence of severe events.
Bone marrow and renal exposure are other considerations for radiopharmaceutical therapy. Radiation delivered to normal tissues may affect blood-cell production or organ function, depending on the treatment’s distribution and cumulative exposure. Dose escalation and repeated administration make these measurements particularly important when developing more intensive treatment schedules.
The initial cohort is not large enough to characterise uncommon adverse events reliably. Its relatively heterogeneous dosing schedules also complicate interpretation because cumulative radiation exposure differs among participants. Larger Phase 2 cohorts and extended follow-up will be needed to determine which adverse effects are associated with the selected regimens and whether they remain manageable during additional cycles.
Why is AdvanCell moving towards induction, maintenance and response-adapted dosing?
The TheraPb Phase 2 expansion is designed to evaluate 160 and 200 megabecquerel treatment activities in a broader group of patients. Rather than simply repeating the original Phase 1 schedule, the programme incorporates an induction phase followed by maintenance and response-adapted dosing. The design allows for up to 12 treatment administrations, compared with the maximum six cycles used during Phase 1.
The rationale is to examine whether treatment intensity can be adjusted according to disease response and individual tolerability. Some patients may benefit from an initial period of more intensive treatment, while others may require a different maintenance schedule. However, the ability to administer more cycles does not automatically mean that longer treatment improves outcomes.
Dose optimisation is especially important for radiopharmaceuticals because both efficacy and toxicity can be related to radiation activity and cumulative exposure. A regimen producing a rapid PSA decline may still be unsuitable if prolonged treatment results in unacceptable normal tissue toxicity. Investigators must therefore consider tumour response, dosimetry and organ function together.
The Phase 2 programme is evaluating both metastatic androgen pathway modulation-sensitive and resistant prostate cancer populations. The resistant population corresponds to the disease setting previously described as metastatic castration-resistant prostate cancer, while the sensitive population includes patients whose disease remains responsive to androgen pathway treatment. These populations differ in prior therapy, disease biology and available standard-of-care options.
The expansion also includes patients who have received prior lutetium-177 PSMA radioligand therapy and those who have not. This distinction is particularly relevant for determining whether ADVC001 might eventually have a role after another PSMA-targeted radiopharmaceutical. Treatment history could influence tumour target expression, disease resistance and the interpretation of clinical responses.
The Phase 2 study will provide an opportunity to investigate whether the response signals observed during Phase 1 persist across these different populations. However, comparing results between subgroups will require consideration of patient characteristics and statistical limitations. The programme remains exploratory and is not yet a confirmatory demonstration of clinical benefit.
Could ADVC001 address resistance to existing metastatic prostate cancer therapies?
Metastatic prostate cancer treatment increasingly includes androgen receptor-directed medicines, chemotherapy, targeted radiopharmaceuticals and selected precision therapies. Although these treatments can produce substantial benefit, many patients eventually experience disease progression. Developing additional options for patients with resistant disease therefore remains an important clinical objective.
PSMA-targeted alpha therapy offers one possible strategy because its radiation characteristics differ from those of beta-emitting radioligands. The ability to deposit high-energy radiation over a short distance may provide activity against certain cancer cell populations. However, that theoretical advantage cannot establish that ADVC001 overcomes resistance to lutetium-177 therapy or other established treatments.
Resistance can arise through several mechanisms, including changes in PSMA expression, tumour heterogeneity and biological adaptations affecting sensitivity to radiation. A different isotope does not eliminate the importance of adequate target expression. Patients with low or heterogeneous PSMA expression may not receive sufficient tumour exposure from a PSMA-targeted treatment.
Future studies will need to determine whether ADVC001 provides durable responses in patients who have progressed following existing therapy. Detailed imaging and treatment-history analyses could help identify populations most likely to benefit. The Phase 2 programme’s inclusion of previously treated patients may therefore provide clinically useful information, although conclusions will depend on the eventual sample size and outcomes.
Another important consideration is whether ADVC001 could be used earlier in the prostate cancer treatment pathway. Investigating metastatic androgen pathway modulation-sensitive disease creates an opportunity to assess the treatment in patients with different disease characteristics. However, moving into earlier-line treatment generally requires a particularly persuasive benefit-risk profile because effective standard therapies are already available.
The programme’s long-term clinical position will depend on the magnitude and durability of benefit relative to those existing options. A biochemical response may justify additional development, but confirmatory evidence would eventually need to address outcomes such as radiographic progression-free survival, symptoms, quality of life and potentially overall survival.
How does AdvanCell’s $315 million financing support its radiopharmaceutical development strategy?
AdvanCell completed an oversubscribed $315 million Series D financing in July 2026, providing substantial resources for its targeted alpha therapy programme. The financing was led by Ally Bridge Group and co-led by Alpha Wave, with participation from investors including Bain Capital Life Sciences, Fidelity Management & Research Company and T. Rowe Price. The company intends to use the proceeds to advance ADVC001 toward Phase 3 development and expand its manufacturing infrastructure.
The financing provides a significant capital base for a company developing a technically complex treatment modality. Radiopharmaceutical research requires capabilities extending beyond conventional drug formulation, including isotope supply, radiolabelling, specialised production facilities and radiation safety systems. Establishing reliable access to these capabilities can influence clinical trial execution and eventual commercial readiness.
AdvanCell describes its operating model as vertically integrated, with capabilities covering lead-212 manufacturing, drug development and radiopharmaceutical production. This structure could provide greater control over selected supply-chain activities compared with relying entirely on external providers. However, vertical integration also requires significant capital investment, specialised personnel and rigorous operational oversight.
The short half-life of lead-212 creates particular logistical considerations. Production, quality testing and distribution must be coordinated with treatment appointments so that sufficient radioactivity remains available when the medicine is administered. Manufacturing facilities and clinical sites may therefore require carefully planned scheduling and transport arrangements.
The company has indicated that its financing will support the expansion of clinical and commercial manufacturing infrastructure. These plans should not be confused with evidence that all required commercial-scale production capabilities are already operational or validated. Future development will require continued investment in quality systems, production capacity and regulatory compliance.
Manufacturing readiness could eventually become a meaningful competitive factor if ADVC001 demonstrates strong clinical results. A therapy with promising efficacy but unreliable isotope availability would face barriers to broad adoption. Conversely, dependable production and distribution could support expansion across specialist oncology centres if regulatory approval is obtained.
What must AdvanCell prove before ADVC001 can progress towards a registration trial?
The updated Phase 1 findings support further investigation because they show biochemical and radiographic evidence of anti-tumour activity, together with encouraging reported tolerability over longer follow-up. However, the study enrolled only 22 participants and used several dose and schedule combinations without a randomised control group. These characteristics limit the strength of conclusions regarding efficacy and comparative safety.
The Phase 2 expansion must establish whether the selected activities and dosing schedules deliver reproducible responses in larger populations. Investigators will need to determine how response rates, progression-free survival and adverse-event patterns vary across treatment settings. The trial may also help identify which patients are most appropriate for subsequent development.
Dose optimisation is likely to remain particularly important because the company is investigating a response-adapted strategy involving additional administrations. Establishing an appropriate cumulative exposure could influence both therapeutic benefit and tolerability. The results will need to account for organ dosimetry and longer-term safety as well as early tumour responses.
The reported 11.2-month median radiographic progression-free survival provides an encouraging signal, but its interpretation requires caution. Without a suitable comparator, the estimate cannot establish that ADVC001 improves outcomes relative to available treatments. The full clinical dataset will also be needed to assess how much follow-up supports the reported median and whether the result is consistent across relevant patient groups.
AdvanCell’s financing provides the resources to pursue a more substantial development programme, while its radiopharmaceutical infrastructure could support eventual production if the therapy succeeds. Neither factor removes the need for controlled clinical evidence. The next meaningful test is whether Phase 2 can identify a regimen with sufficiently robust efficacy, safety and dosimetry data to justify confirmatory development.
The updated TheraPb results position ADVC001 as an investigational therapy with promising early activity in PSMA-positive metastatic prostate cancer. Its potential role will become clearer only after larger cohorts establish whether the observed responses are durable, reproducible and accompanied by an acceptable treatment burden. For a field already transformed by PSMA-targeted radioligand therapy, AdvanCell must ultimately demonstrate that its lead-212 approach offers a clinically meaningful advance rather than simply a different radioactive payload.
